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Other names: FLJ20648; FLJ39787; ZZANK1;  
5; Skeletrophin; novelzin 
Location: 1p36.33 
Local order: ATAD3A (ATPase family, AAA domain 
containing 3B), is more telomeric, CDC2L2 (cell 
division cycle 2-like 2) is more centromeric. 
Note: Orientation: plus strand. 
DNA/RNA 
Note: There are at least six alternative splicing forms. 
 
Genomic structure of Mib2/skeletrophin 
Description 
20 Exons spanning 14 kb on 1p36.33. 
Protein 
Note: The number of amino acids are varied in each 
splicing form. 
Expression 
Human mib2/skeletrophin is strongly expressed in adult 




Ubiquitin ligase to cytoplasmic domain of Notch 
ligands and NMDA receptor GRIN2B/NR2B subunit. 
Putative positive regulation of I-kappaB kinase/NF-
kappaB cascade. 
Homology 
The protein structure of mib2/skeletrophin is closely 
related to MIB1 (mind bomb-1 homolog). 
Implicated in 
Malignant melanoma, vertical growth 
phase. 
Oncogenesis 
Putative suppressor factor against malignant melanoma 
invasion. In invasive malignant melanoma, 
Mib2/skeletrophin gene expression is down-regulated 
by various epigenetic events described below. The 
promoter region of Mib2/skeletrophin gene contains 
typical CpG islands, which is hypermethylated in 
invasive malignant melanoma. A zinc-finger 
transcriptional factor Snail, which is overexpressed in 
many melanoma cells, repressed the Mib2/skeletrophin 
promoter activity via an E-box-related element.  
An activator protein-2, which has a tumor suppressor-





Schematic illustrating of mib2/skeletrophin. 
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Multiple myeloma, especially at 
advanced stage with osteolytic lesion. 
Oncogenesis 
Putative oncogenic factor for multiple myeloma 
thorough bone marrow microenvironments. In multiple 
myeloma, Mib2/skeletrophin and its substrates, Jagged-
1 and Jagged-2, are both overexpressed in bone marrow 
microenvironments. Ligands-dependent Notch 
activation is occurred by direct cell-cell interaction 
between multiple myeloma cells and bone marrow 
stromal cells and contribute the myeloma niche, which 
is known as microenvironment suitable for 
myelomagenesis. 
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